Sant Joan de Déu coordinates the European project AriChall, an international initiative that promotes a new clinical trial with the aim of identifying a treatment for children with acute lymphoblasti...
Read moreRegulatory guidance recognizes that advanced therapy medicinal products differ fundamentally from conventional drugs because variability may arise from living systems, manufacturing environments, and ...
Read moreLa investigación, cuyos resultados se han publicado en European Journal of Haematology, se ha centrado en analizar las bacterias que influyen en la respuesta o la toxicidad del tratamiento, por trata...
Read moreEl Dr. Jordi Antón, jefe del Servicio de Reumatología Pediátrica de Sant Joan de Déu, explica los avances en la aplicación de las terapias CAR-T en las enfermedades autoinmunes sistémicas pediá...
Read moreLa CEO y cofundadora de WIVI VISION, reconocida por Forbes entre las 35 Techwomen de 2024, asume la presidencia de la principal comunidad empresarial del sector de la salud en Cataluña
Read moreDesarrollan un hidrogel, biomaterial inteligente que funciona como vehículo de células en la terapia celular para el tratamiento de enfermedades neurológicas caracterizadas por la pérdida de miel...
Read morePolymers are emerging as powerful alternatives to viral vectors for DNA delivery, enabling safer and more flexible approaches for DNA vaccines and in vivo CAR-T therapies.
Read moreA UAB research team defines the criteria that CAR immunotherapies for neurodegenerative diseases must meet to advance both conceptually and in trials, which are still at a very preliminary stage, in a...
Read moreAfter more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del Mar Research Institute, has been administered to patients for the first t...
Read morePartnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo lentiviral vectors for the advanced therapies sector
Read moreAccelerate functional assays with a specialized ecosystem of native tumor lines, engineered antigens, and quantitative reporter systems.
Read moreEl escenario regulatorio de las Terapias Avanzadas es complejo. En él conviven autorizaciones de uso hospitalario con medicamentos plenamente aprobados por la EMA. Entender esta dualidad permite anti...
Read more